CNSP vs. CMND, DRMA, ATXI, CYTO, GLMD, SLRX, SNOA, NTBL, ALLR, and ONCO
Should you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Clearmind Medicine (CMND), Dermata Therapeutics (DRMA), Avenue Therapeutics (ATXI), Altamira Therapeutics (CYTO), Galmed Pharmaceuticals (GLMD), Salarius Pharmaceuticals (SLRX), Sonoma Pharmaceuticals (SNOA), Notable Labs (NTBL), Allarity Therapeutics (ALLR), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.
Clearmind Medicine (NASDAQ:CMND) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their community ranking, risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
In the previous week, CNS Pharmaceuticals had 4 more articles in the media than Clearmind Medicine. MarketBeat recorded 4 mentions for CNS Pharmaceuticals and 0 mentions for Clearmind Medicine. CNS Pharmaceuticals' average media sentiment score of 1.25 beat Clearmind Medicine's score of 0.46 indicating that Clearmind Medicine is being referred to more favorably in the media.
Clearmind Medicine has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.78, suggesting that its share price is 178% more volatile than the S&P 500.
CNS Pharmaceuticals received 46 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 9.2% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
CNS Pharmaceuticals' return on equity of -265.38% beat Clearmind Medicine's return on equity.
Summary
Clearmind Medicine beats CNS Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get CNS Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CNS Pharmaceuticals Competitors List
Related Companies and Tools
